NME Class of 2006?

NME Class of 2006?
These 23 drugs have been assigned user fee dates in 2006 and could be among the new molecular entities approved this year, based on public disclosure.
Drug	Company	Estimated Action Date
Acomplia	Sanofi-Aventis	2/2006
Arformoterol	Sepracor	10/13/2006*
Champix	Pfizer	5/2006
Dacogen	MGI/SuperGen	5/15/2006
Dasatinib	Bristol-Myers Squibb	6/28/2006 or 10/28/2006* (Priority review requested)
Desvenlafaxine	Wyeth	10/22/2006
Dronedarone	Sanofi-Aventis	4/2006
Exubera	Pfizer/Sanofi-Aventis	1/27/2006
Genasense	Genta	6/29/2006 or 10/29/2006** (Priority review requested)
Hexvix	PhotoCure ASA	4/30/2006
Indiplon	Pfizer/Neurocrine	2/15/2006
Lubiprostone	Sucampo	1/31/2006
Neupro	Schwarz	2/28/2006
NRP104	Shire/New River	6/6/2006 or 10/6/2006**
Nuvigil	Cephalon	1/31/2006
Paliperidone	Johnson & Johnson	9/29/2006
Polyphenon E	MediGene AG	7/28/2006*
Ranexa	CV Therapeutics	1/27/2006
Rufinamide	Eisai	9/16/2006
Sutent	Pfizer	2/10/2006
Telbivudine	Novartis/Idenix	11/3/2006*
Thelin	Encysive	3/24/2006
TMC-114	Johnson & Johnson	6/23/2006 or 10/23/2006**
* Date based on announcement of submission; approval could come earlier ** Status as priority or standard review unknown